scholarly journals Donald Metcalf AC. 26 February 1929 — 15 December 2014

2016 ◽  
Vol 62 ◽  
pp. 409-431
Author(s):  
Nicos A. Nicola
Keyword(s):  
Growth Factors ◽  
Progenitor Cells ◽  
Human Health ◽  
Cancer Patients ◽  
Mechanisms Of Action ◽  
Clinical Use ◽  
Medical Researchers

Donald Metcalf was one of Australia's most distinguished medical researchers and is acknowledged internationally as the father of the modern field of haemopoietic growth factors. He defined the hierarchy of haemopoietic progenitor cells, purified and cloned the major molecular regulators of their growth and maturation, determined their mechanisms of action and participated in their development for clinical use in cancer patients. He received numerous awards and distinctions during his career, but was most pleased by the fact that his life's work improved human health.

Donald Metcalf 1929–2014

2016 ◽  
Vol 27 (2) ◽  
pp. 176 ◽  
Author(s):  
Nicos A. Nicola
Keyword(s):  
Growth Factors ◽  
Progenitor Cells ◽  
Human Health ◽  
Cancer Patients ◽  
Mechanisms Of Action ◽  
Clinical Use ◽  
Medical Researchers

Donald Metcalf was one of Australia's most distinguished medical researchers and is acknowledged internationally as the father of the modern field of haemopoietic growth factors. He defined the hierarchy of haemopoietic progenitor cells, purified and cloned the major molecular regulators of their growth and maturation, determined their mechanisms of action and participated in their development for clinical use in cancer patients. He received numerous awards and distinctions during his career, but was most pleased by the fact that his life's work improved human health.

scholarly journals Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3540
Author(s):  
Hamid Maadi ◽  
Mohammad Hasan Soheilifar ◽  
Won-Shik Choi ◽  
Abdolvahab Moshtaghian ◽  
Zhixiang Wang
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Mechanism Of Action ◽  
Mechanisms Of Action ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Insight Into ◽  
Positive Breast Cancer

Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998. Although trastuzumab has opened a new avenue to treat patients with HER2-positive breast cancer and other types of cancer, some patients are not responsive or become resistant to this treatment. So far, several mechanisms have been suggested for the mode of action of trastuzumab; however, the findings regarding these mechanisms are controversial. In this review, we aimed to provide a detailed insight into the various mechanisms of action of trastuzumab.

scholarly journals Ex vivo expansion of human hematopoietic stem and progenitor cells

Blood ◽  
2011 ◽  
Vol 117 (23) ◽  
pp. 6083-6090 ◽  
Author(s):  
Ann Dahlberg ◽  
Colleen Delaney ◽  
Irwin D. Bernstein
Keyword(s):  
Stem Cell ◽  
Growth Factors ◽  
Notch Signaling ◽  
Progenitor Cells ◽  
Ex Vivo ◽  
Ex Vivo Expansion ◽  
Hematopoietic Growth Factors ◽  
Self Renewal ◽  
Hematopoietic Stem ◽  
Stem And Progenitor Cells

AbstractDespite progress in our understanding of the growth factors that support the progressive maturation of the various cell lineages of the hematopoietic system, less is known about factors that govern the self-renewal of hematopoietic stem and progenitor cells (HSPCs), and our ability to expand human HSPC numbers ex vivo remains limited. Interest in stem cell expansion has been heightened by the increasing importance of HSCs in the treatment of both malignant and nonmalignant diseases, as well as their use in gene therapy. To date, most attempts to ex vivo expand HSPCs have used hematopoietic growth factors but have not achieved clinically relevant effects. More recent approaches, including our studies in which activation of the Notch signaling pathway has enabled a clinically relevant ex vivo expansion of HSPCs, have led to renewed interest in this arena. Here we briefly review early attempts at ex vivo expansion by cytokine stimulation followed by an examination of our studies investigating the role of Notch signaling in HSPC self-renewal. We will also review other recently developed approaches for ex vivo expansion, primarily focused on the more extensively studied cord blood–derived stem cell. Finally, we discuss some of the challenges still facing this field.

Prospects for immunomodulatory therapy of bronchial asthma

1998 ◽  
Vol 79 (5) ◽  
pp. 388-391
Author(s):  
G. V. Cherepnev ◽  
Y. D. Slabnov ◽  
I. E. Zimakova
Keyword(s):  
Bronchial Asthma ◽  
Russian Federation ◽  
Mechanisms Of Action ◽  
Immunomodulatory Therapy ◽  
Immune Homeostasis ◽  
Clinical Use ◽  
Immunological Reactivity ◽  
The Past ◽  
The Russian Federation ◽  
Pharmacological Correction

The relevance of pharmacological correction of immunological reactivity is obvious: many socially significant diseases are accompanied by an imbalance in immune homeostasis. In the past few years, a number of reviews on the classification and mechanisms of action of immunotropic drugs approved for clinical use in the Russian Federation have been published in the domestic press.

Estimation of Nickel in Different Smokeless Tobacco Products and Their Impact on Human Health of Oral Cancer Patients

2015 ◽  
Vol 67 (7) ◽  
pp. 1063-1074 ◽  
Author(s):  
Sadaf S. Arain ◽  
Tasneem G. Kazi ◽  
Hassan I. Afridi ◽  
Farah N. Talpur ◽  
Atif G. Kazi ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Human Health ◽  
Cancer Patients ◽  
Smokeless Tobacco ◽  
Tobacco Products ◽  
Smokeless Tobacco Products ◽  
Oral Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document